Journal of Personalized Medicine (Dec 2022)

Hereditary Diffuse Gastric Cancer: A 2022 Update

  • Christo Kole,
  • Nikolaos Charalampakis,
  • Stratigoula Sakellariou,
  • George Papaxoinis,
  • Konstantinos G. Apostolou,
  • Nikolaos Machairas,
  • Ioannis S. Papanikolaou,
  • Dimitrios Schizas

DOI
https://doi.org/10.3390/jpm12122032
Journal volume & issue
Vol. 12, no. 12
p. 2032

Abstract

Read online

Gastric cancer is ranked fifth among the most commonly diagnosed cancers, and is the fourth leading cause of cancer-related deaths worldwide. The majority of gastric cancers are sporadic, while only a small percentage, less than 1%, are hereditary. Hereditary diffuse gastric cancer (HDGC) is a rare malignancy, characterized by early-onset, highly-penetrant autosomal dominant inheritance mainly of the germline alterations in the E-cadherin gene (CDH1) and β-catenin (CTNNA1). In the present study, we provide an overview on the molecular basis of HDGC and outline the essential elements of genetic counseling and surveillance. We further provide a practical summary of current guidelines on clinical management and treatment of individuals at risk and patients with early disease.

Keywords